The appointment is fifteen minutes. The doctor is kind but moving fast. You came in wanting to ask about a newer depression treatment, and specifically whether it is FDA-approved and whether your employer plan will pay for it. Then the visit starts and the questions go right out of your head.
This script is meant to fix that. It gives you the words to ask about FDA status and coverage, in an order that makes sense, so you leave with answers instead of a pamphlet.
Why these two questions belong together
Our commissioned survey of 443 Midwest adults suggests people give both questions real weight. On FDA approval, 59 percent told us it would be big or decisive in their choice about a new depression treatment. On insurance, the matching share was 65 percent. Both numbers come from the validated final data. Respondents on employer or other commercial coverage, 173 in all, split the two differently: 54 percent for FDA approval, 67 percent for insurance.
For people with commercial insurance, the two questions often lead to the same place. Plans tend to have clearer coverage rules for treatments used for their FDA-approved purpose. Off-label uses are more likely to be denied or left for you to pay.
And your doctor is the right person to ask. Our respondents were clear on who could persuade them to try something new: a personal doctor's recommendation won with 74 percent, far ahead of every other source.
Before the visit
- Jot down each antidepressant you have taken, roughly what dose, and your time on it. Insurers ask for this.
- Look up your plan's member services number and have your card handy.
- Decide what matters most to you: a drug-free option, a supervised setting, something you can do near home, or the fastest path to starting.
Opening the conversation
Start with how you feel, not with a treatment name. It gives the doctor context.
"The medications I've tried haven't done enough. I'm still struggling most days, and I'd like to hear what other options exist for someone like me."
Then, if you have something specific in mind:
"I've read about esketamine, the nasal spray. I'm also curious about TMS. Could either of those make sense for me?"
Asking about FDA status
These questions help you understand what category a treatment falls into.
- "Is this FDA-approved for my condition, or would it be an off-label use?"
- "Is it approved as a drug or cleared as a device?"
- "What does the approval actually cover, and do I fit that description?"
Useful background: esketamine, the drug in Spravato, has an FDA approval covering depression that earlier treatment did not resolve, and each dose is supervised inside a certified clinic. Before the visit you could print this Brain Recovery Centers page on Spravato treatment. TMS is different again: a magnetic device carrying FDA clearance, used when antidepressants have not moved the needle on depression. IV ketamine used for depression is an approved anesthetic prescribed off-label. Ketamine sold for use at home lacks FDA approval for depression.
Asking about coverage
Your doctor may not know the details of your plan, but they know what paperwork insurers usually want.
- "What will my plan likely require before approving this?"
- "Do my records already show the medication trials they will ask for?"
- "Will your office submit the prior authorization, or does the treating clinic?"
- "Is there a clinic you refer to that is usually in network for plans like mine?"
Asking about the practical side
- "How many visits a week, and over how many weeks?"
- "Will I be able to drive myself home?" (For esketamine, no: you wait until the following day, after sleeping.)
- "What happens if it doesn't help?"
If the doctor is unfamiliar with the option
This happens, and it is not a sign of a bad doctor. You can say:
"Is there a psychiatrist you trust who could look at whether this fits me?"
A psychiatric referral is often part of the path anyway. Our survey found 23 percent would bypass the family doctor and start with a psychiatrist.
When the answer is "not for you"
Ask why. It is a fair question and you deserve to understand the reasoning.
"What in my history rules it out? Could anything change that later?"
Then ask what they would suggest instead. The goal of the visit is a next step, not a specific treatment.
After the visit: call your plan
Once you have a treatment name, call member services and ask:
- "Is this covered, and under my medical benefit, pharmacy benefit, or both?"
- "Is prior authorization required? Can you send me the policy criteria?"
- "Is this clinic in network for this service?"
- "What is my deductible status and my share per visit?"
For FDA-approved drugs like esketamine, also ask the clinic whether a manufacturer savings program applies to you and whether it covers the office visit or just the medication.
If the plan says no
A first denial is common and often fixable. Ask the plan for the denial reason in writing, then share it with your doctor's office. Many denials come down to a missing detail, such as an undocumented medication trial or a missing diagnosis code. An internal appeal is your right, and many plans also allow an external review by an independent reviewer if that fails. A short letter from your doctor explaining why the treatment fits the approved use can carry real weight.
Keeping it in proportion
FDA approval and coverage are important filters, but they do not decide whether a treatment is right for you. Your history, health, and goals decide that, which is why the call belongs with a clinician. Use this script as general information, never as medical advice for your own case.
If you are thinking about taking your own life, skip the script and reach out now. Calling or texting 988 brings a confidential, no-charge Suicide and Crisis Lifeline counselor onto the line at any hour.
Methodology
The figures in this script come from a Pollfish consumer panel survey; the publisher commissioned it and covered the fee. When the survey shut on June 23, 2026, it had drawn replies from 443 adults, each 18 to 64, spread across Iowa, Indiana, Illinois, Minnesota, Nebraska, Kansas, Wisconsin, Oklahoma, Missouri, and Ohio. Apart from the commercial insurance figures, results cover the whole sample, all final after Pollfish's validation.